NON-ALKOLİK STEATOHEPATİT TEDAVİSİNDE N-ASETİL SİSTEİN KULLANIMI
Giriş: Yağlı karaciğer (hepatosteatoz) terimi trigliseridlerin karaciğer ağırlığının %5'ini geçecek şekilde birikimidir. Hepatosteatoza inflamasyonun eşlik ettiği Mallory hyalin cisimcikleri, fibrozis ve sirozisin eşlik ettiği durumlar nonalkolik steatohepatit (NASH) olarak tanımlanır. Mukolitik etkinliği nedeniyle solunum yolu hastalıklarında kullanılan, ancak antioksidan etkinliği bilinen N-Asetil Sisteinin (NAC), NASH tedavisinde etkin olabileceği düşünülmektedir. Gereç ve Yöntem: Batın ultrasonografisinde hepatosteatoz tespit edilen 12 olgu çalışma kapsamında incelendi. Bulgular: Karaciğer sirozuna dönüşüm potansiyeli nedeniyle klinik olarak son dönem karaciğer yetmezliği riski altında bulunan bu grup hastaların tedavisinde, NAC’ın yerini belirlemek amacıyla, biyokimyasal ve histopatolojik bulguları değerlendirildi. Sonuç: NASH'deki biyokimyasal parametreler ve makroveziküler steatozis üzerine NAC’ın etkisi anlamlı bulunmuştur ve kesin etkilerinin belirlenebilmesi için, daha fazla sayıda vaka içeren, daha uzun süreli çalışmalara ihtiyaç vardır.
N-ACETYL SISTEIN USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
Introduction:Fatty liver (hepatosteatosis) is the accumulation of triglycerides that exceeds 5% of the liver weight. Non-alcoholic steatohepatitis (NASH) is a liver disease characterized by macrovesicular steatosis, hepatocytenecrosis, inflammation, Mallory bodies, and fibrosis.N-acetylcysteine (NAC) which have an antioxidant effect can improve liver function in patients within on-alcoholic fatty liver disease. Material and methods: Twelve cases with hepatosteatosis detected in the abdominal ultrasonography were evaluated in this study. Results: In our study, we evaluated biochemstrical and histopathologic findings in the treatment of these group of patients who are clinically suspected of having end-stage liver failure due to the potential for conversion to liver cirrhosis in order to determine the effect of the NAC. Conclusion: The effect of NAC was found to be significant on the biochemical parameters and macrovessel steatosis in NASH. There is a need for longer periods of work with more cases in order to determine their exact impact.
___
- Ludwig J, Viggiano TR, McGill DB. Nonalcoholic steatohepatitis: Mayo ClinicProc 1980; 55(7):342 -8.
- Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intem Med 1997;126(2) :137- 45.
- Mirhafez SR, Avan A, Pasdar A, Kazemi E, Ghasemi F, Tajbakhsh A, et al. Association of tumor necrosisfactor-α promoter G-308A gene polymorphism with increased triglycerid elevel of subjects with metabolic syndrome. Gene 2015; 568(1): 81-4.
- Day CP, James OFW. Steatohepatitis: a tale of two"hits"? Gastroenterolgy 1998; 114(4):842-45.
- Socha P, Wierzbicka A, Neuhoff-Murawska J. Nonalcoholic fatty liver disease as a feature of the metabolic syndrome. Rocz Panstw Zakl Hig. 2007;58(1):129-37.
- Day CP, Saksene S.Nonalcoholic steatohepatitis: Defınitions and pathogenesis. J Gastroenterology 2002;17( 3):377-84.
- Baumgardner JN, Shankar K, Hennings L. A new model for nonalcoholic steatohepatitis in the ratutilizing total enteral nutrition to overfeed a high polyunsaturated fat diet. Am J PhysiolGastrointestLiverPhysiol. 2008;294(1):27-38.
- Graff M, North KE, Franceschini N, Reiner AP, Feitosa M, Carr JJ, et al. PNPLA3 gene-by-visceral adipose tissue volume interaction and the pathogenesis of fatty liver disease: the NHLBI family heart study. Int J Obes (Lond). 2013;37(3):432-8.
- Ballestri S, Nascimbeni F, Romagnoli D. The independent predictors of non-alcoholic steatohepatitis and its individual histological features: Insulin resistance, serum uric acid, metabolic syndrome, alanine amino transferase and serum total cholesterolare a clue to pathogenesis and candidate targets for treatment. HepatolRes. 2016;46(11):1074-87.
- Salve VT, Atram JS. N-Acetylcysteine combined with home based physical activity: Effect on health related quality of life in stable COPD patients-A randomised controlled trial. J ClinDiagn Res. 2016;10(12):16-19.
- Jouett NP, Moralez G, White DW, Eubank WL, Chen S, Tian J, et al. N-Acetylcysteine reduces hyperacute intermittent hypoxia-induced sympathoexcitation in human subjects.ExpPhysiol. 2016;101(3):387-96.
- Zhao ZH, Liu XL, Fan JG. Research on the natural history of non-alcoholic fatty liver disease should be taken seriously. ZhonghuaGanZang Bing ZaZhi. 2017; 25(2):81-4.
- Klein S, Mittendorfer B, Eagon JC, Patterson B, Grant L, Feirt N, et al. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology. 2006;130(6):1564-72.
- ISSN: 1305-5151
- Başlangıç: 1995
- Yayıncı: İzmir Bozyaka Eğitim ve Araştırma Hastanesi
Sayıdaki Diğer Makaleler
NON-ALKOLİK STEATOHEPATİT TEDAVİSİNDE N-ASETİL SİSTEİN KULLANIMI
Bilge BAŞ, Erkan OYMACI, Haydar ADANIR
İZOLE HİPOGLİSEMİ NEDENİ: SHEEHAN SENDROMU (SS)
Emre GEZER, Gökçen ÜNAL KOCABAŞ, Arif YÜKSEL
Yusuf ŞENOĞLU, Ali TEKİN, Gizem DEMİR ŞENOĞLU
Arif YÜKSEL, Bülent ALKAN, Didem YÜKSEL, Ege KARAMANCI, Oktay BİLGİR, Giray BOZKAYA, Erhan ERGİN
Arif YÜKSEL, Erhan ERGİN, Bülent ALKAN, Didem YÜKSEL, Giray BOZKAYA, Ege KARAMANCI, Oktay BİLGİR
Bumin ÖRS, Yasin CEYLAN, Ömer KORAŞ, Kutsan ÇÖKTÜ, HAKAN MURAT ARSLAN, Süleyman MİNARECİ, Timuçin ŞİPAL, BÜLENT GÜNLÜSOY